Clinical Research Directory

Inclusion Criteria: * Subjects who self-report their race/ethnicity as Black-non-Hispanic only (which may include self-reported African ancestry as African-American, Afro-Caribbean or African) * Subjects receiving a first or second deceased donor or living donor kidney transplant at the Hospital of the University of Pennsylvania * Subjects whose body mass index (BMI) ≥19 * Subjects who are sero-positive for Hepatitis B or C positive may also be enrolled. * Subjects whose concurrent immunosuppression at the time of transplant will be (generic or brand formulation) Mycophenolate mofetil (MMF, CellCept) or mycophenolic sodium (MPS, Myfortic®), either a standard prenisone taper or an early withdrawal protocol, and induction with rabbit-antithymocyte globulin (Thymoglobulin®). Exclusion Criteria: * Subjects who are greater than 75 years old * Known hypersensitivity to Tacrolimus and hydrogenated castor oil * Subjects who are not self-described as being of Black African descent and living in the United States * Subjects who self-report their race/ethnicity as Black-Hispanic or Multiracial * Subjects who are recipients of organ transplants other than kidney * Subjects who are recipients of third time or more kidney transplants * Subjects who are HIV positive at the time of pre-transplant screening * Subjects with recurrent focal segmental glomerulosclerosis (FSGS) * Subjects with any severe medical condition (including infection or severe liver disease) requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation * Subjects with WBC ≤ 2000/mm3 or ANC ≤ 1500 mm3 with PLT ≤ 75,000/mm3 or HGB \< 8 g/dL * Subjects with mental or physical conditions or known non-adherence (defined as documentation in the patient chart of multiple missed visits and/or medication doses) which in the investigator's opinion would interfere with the objectives of the study * Subjects who have been exposed to investigational therapy within 30 days prior to enrollment or five half-lives of the investigational product (whichever is greater). * Subjects with severe diabetic gastroparesis or other severe GI disturbances that could interfere with Tacrolimus absorption * Subjects who have underwent gastric bypass at any time pre transplant. * Pregnant or nursing (lactating) women subjects, where pregnancy is defined as a state of female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/ml). * Women subjects of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a double-barrier method of contraception, UNLESS they are * Women whose career, lifestyle, or sexual orientation preclude intercourse with a male partner * Women whose partners have been sterilized by vasectomy or other means